vs

Side-by-side financial comparison of Arcutis Biotherapeutics, Inc. (ARQT) and PicoCELA Inc. (PCLA). Click either name above to swap in a different company.

PicoCELA Inc. is the larger business by last-quarter revenue ($252.6M vs $129.5M, roughly 2.0× Arcutis Biotherapeutics, Inc.). Arcutis Biotherapeutics, Inc. runs the higher net margin — 13.4% vs -125.2%, a 138.6% gap on every dollar of revenue.

Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.

PicoCELA Inc. is a global technology company specializing in low-power, high-reliability wireless connectivity solutions, including Wi-Fi HaLow modules and edge network infrastructure. It caters to industrial IoT, smart city, retail, and smart home segments, with a primary operational footprint across Asia, North America, and European markets.

ARQT vs PCLA — Head-to-Head

Bigger by revenue
PCLA
PCLA
2.0× larger
PCLA
$252.6M
$129.5M
ARQT
Higher net margin
ARQT
ARQT
138.6% more per $
ARQT
13.4%
-125.2%
PCLA

Income Statement — Q2 FY2026 vs Q2 FY2025

Metric
ARQT
ARQT
PCLA
PCLA
Revenue
$129.5M
$252.6M
Net Profit
$17.4M
$-316.2M
Gross Margin
91.0%
Operating Margin
14.2%
-114.8%
Net Margin
13.4%
-125.2%
Revenue YoY
81.5%
Net Profit YoY
EPS (diluted)
$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARQT
ARQT
PCLA
PCLA
Q2 26
$129.5M
Q1 26
$105.4M
Q4 25
$129.5M
Q3 25
$99.2M
Q2 25
$81.5M
Q1 25
$65.8M
$252.6M
Q4 24
$71.4M
Q3 24
$44.8M
Net Profit
ARQT
ARQT
PCLA
PCLA
Q2 26
$17.4M
Q1 26
$-11.3M
Q4 25
$17.4M
Q3 25
$7.4M
Q2 25
$-15.9M
Q1 25
$-25.1M
$-316.2M
Q4 24
$-10.8M
Q3 24
$-41.5M
Gross Margin
ARQT
ARQT
PCLA
PCLA
Q2 26
91.0%
Q1 26
90.7%
Q4 25
91.0%
Q3 25
91.2%
Q2 25
90.8%
Q1 25
86.6%
Q4 24
90.3%
Q3 24
87.7%
Operating Margin
ARQT
ARQT
PCLA
PCLA
Q2 26
14.2%
Q1 26
-8.6%
Q4 25
14.2%
Q3 25
8.6%
Q2 25
-17.9%
Q1 25
-37.3%
-114.8%
Q4 24
-10.7%
Q3 24
-87.3%
Net Margin
ARQT
ARQT
PCLA
PCLA
Q2 26
13.4%
Q1 26
-10.7%
Q4 25
13.4%
Q3 25
7.5%
Q2 25
-19.5%
Q1 25
-38.1%
-125.2%
Q4 24
-15.1%
Q3 24
-92.8%
EPS (diluted)
ARQT
ARQT
PCLA
PCLA
Q2 26
$0.13
Q1 26
$-0.09
Q4 25
$0.14
Q3 25
$0.06
Q2 25
$-0.13
Q1 25
$-0.20
Q4 24
$-0.09
Q3 24
$-0.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARQT
ARQT
PCLA
PCLA
Cash + ST InvestmentsLiquidity on hand
$42.9M
$456.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$189.5M
$354.8M
Total Assets
$433.0M
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARQT
ARQT
PCLA
PCLA
Q2 26
$42.9M
Q1 26
$34.8M
Q4 25
$42.9M
Q3 25
$47.1M
Q2 25
$72.7M
Q1 25
$53.1M
$456.8M
Q4 24
$71.3M
Q3 24
$134.9M
Total Debt
ARQT
ARQT
PCLA
PCLA
Q2 26
Q1 26
Q4 25
$109.0M
Q3 25
$108.5M
Q2 25
$108.0M
Q1 25
$107.6M
Q4 24
$107.2M
Q3 24
$204.6M
Stockholders' Equity
ARQT
ARQT
PCLA
PCLA
Q2 26
$189.5M
Q1 26
$189.6M
Q4 25
$189.5M
Q3 25
$158.1M
Q2 25
$139.0M
Q1 25
$142.7M
$354.8M
Q4 24
$157.5M
Q3 24
$156.6M
Total Assets
ARQT
ARQT
PCLA
PCLA
Q2 26
$433.0M
Q1 26
$460.0M
Q4 25
$433.0M
Q3 25
$371.0M
Q2 25
$352.4M
Q1 25
$344.1M
$1.2B
Q4 24
$348.9M
Q3 24
$437.4M
Debt / Equity
ARQT
ARQT
PCLA
PCLA
Q2 26
Q1 26
Q4 25
0.58×
Q3 25
0.69×
Q2 25
0.78×
Q1 25
0.75×
Q4 24
0.68×
Q3 24
1.31×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARQT
ARQT
PCLA
PCLA
Operating Cash FlowLast quarter
$-245.6M
Free Cash FlowOCF − Capex
$-256.6M
FCF MarginFCF / Revenue
-101.6%
Capex IntensityCapex / Revenue
4.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARQT
ARQT
PCLA
PCLA
Q2 26
Q1 26
Q4 25
$26.2M
Q3 25
$-1.8M
Q2 25
$324.0K
Q1 25
$-30.4M
$-245.6M
Q4 24
$-748.0K
Q3 24
$-34.7M
Free Cash Flow
ARQT
ARQT
PCLA
PCLA
Q2 26
Q1 26
Q4 25
Q3 25
Q2 25
$246.0K
Q1 25
$-31.0M
$-256.6M
Q4 24
Q3 24
$-34.8M
FCF Margin
ARQT
ARQT
PCLA
PCLA
Q2 26
Q1 26
Q4 25
Q3 25
Q2 25
0.3%
Q1 25
-47.1%
-101.6%
Q4 24
Q3 24
-77.8%
Capex Intensity
ARQT
ARQT
PCLA
PCLA
Q2 26
Q1 26
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.1%
Q1 25
0.9%
4.3%
Q4 24
0.0%
Q3 24
0.3%
Cash Conversion
ARQT
ARQT
PCLA
PCLA
Q2 26
Q1 26
Q4 25
1.51×
Q3 25
-0.24×
Q2 25
Q1 25
Q4 24
Q3 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARQT
ARQT

Segment breakdown not available.

PCLA
PCLA

Revenue from product$179.1M71%
Revenue from SaaS, Maintenance and others$42.4M17%
Revenue from product – related party$31.0M12%

Related Comparisons